Cytosorbents Corp.
Veridion Score
Composite trend over time
Why is CTSO moving today?
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for CTSO.
CTSO insider activity
Cytosorbents Corp.
2 insiders bought in the last 90 days
Net buying: $213K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | 2026-06-15 | MARIANI PETER J | Insider | buy | $0.44 | 100,000 | 638,113 | $44K | SEC Form 4 |
| 2026-06-15 | 2026-06-15 | Chan Phillip P. | Insider | buy | $0.43 | 10,333 | 1,744,432 | $4K | SEC Form 4 |
| 2026-06-15 | 2026-06-12 | Chan Phillip P. | Insider | buy | $0.40 | 251,136 | 1,734,099 | $100K | SEC Form 4 |
| 2025-11-20 | 2025-11-18 | Chan Phillip P. | Insider | buy | $0.64 | 100,000 | 1,482,963 | $64K | SEC Form 4 |
CTSO contract awards, year to date.
Public federal awards linked to this ticker.
CTSO lobbying filings, year to date.
Registered lobbying filings matched to Cytosorbents Corp..